154 related articles for article (PubMed ID: 22238151)
1. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Karuri SW; Simon R
Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
4. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Jiang W; Freidlin B; Simon R
J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
7. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
8. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
9. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
10. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
11. A practical guide to Bayesian group sequential designs.
Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
[TBL] [Abstract][Full Text] [Related]
12. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
13. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
14. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
15. Optimal Bayesian design for patient selection in a clinical study.
Buzoianu M; Kadane JB
Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial designs for predictive marker validation in cancer treatment trials.
Sargent DJ; Conley BA; Allegra C; Collette L
J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
[TBL] [Abstract][Full Text] [Related]
17. A simple Bayesian decision-theoretic design for dose-finding trials.
Fan SK; Lu Y; Wang YG
Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943
[TBL] [Abstract][Full Text] [Related]
18. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
19. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
20. A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery.
Smith NR; Womack C
J Pathol; 2014 Jan; 232(2):190-8. PubMed ID: 24030847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]